Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a report issued on Wednesday morning,Benzinga reports. The firm currently has a $33.00 price objective on the stock. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.57 EPS, FY2027 earnings at $1.85 EPS, FY2028 earnings at $2.87 EPS and FY2029 earnings at $3.74 EPS.

A number of other analysts also recently issued reports on ETON. B. Riley started coverage on shares of Eton Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $21.00 price target on the stock. Craig Hallum lifted their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th.

Eton Pharmaceuticals Stock Down 3.8 %

ETON stock opened at $14.22 on Wednesday. The business’s 50-day moving average price is $15.58 and its 200-day moving average price is $11.54. The stock has a market cap of $370.45 million, a P/E ratio of -64.64 and a beta of 1.37. Eton Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON) last released its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). The firm had revenue of $11.65 million during the quarter, compared to analysts’ expectations of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. On average, equities research analysts expect that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eton Pharmaceuticals in the 3rd quarter valued at about $54,000. Tower Research Capital LLC TRC bought a new stake in Eton Pharmaceuticals during the fourth quarter worth approximately $86,000. Jane Street Group LLC purchased a new stake in Eton Pharmaceuticals during the third quarter valued at approximately $90,000. Jefferies Financial Group Inc. bought a new stake in shares of Eton Pharmaceuticals in the 4th quarter valued at approximately $133,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Eton Pharmaceuticals in the 4th quarter worth approximately $147,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.